U.K. scientists examined a type of leukemia caused by the faulty mixed lineage leukemia gene and found that leukemic stem cells could be converted back to a precancerous phase by inhibiting a protein in the blood. "The findings provide compelling evidence that this protein could be exploited to develop an effective therapeutic target for this form of the disease," the lead researcher said.

Full Story:

Related Summaries